Boston Scientific (BSX) Reports Q1 Results; Guides Q2, Raises FY11 Outlook
Tweet
Share
E-mailGet Alerts BSX Hot Sheet
Price: $67.33 -0.13%
Revenue Growth %: +8.6%
Financial Fact:
Net income (loss) per common share - assuming dilution: 0.17
Today's EPS Names:
MAXN, CSTR, ACU, More
Revenue Growth %: +8.6%
Financial Fact:
Net income (loss) per common share - assuming dilution: 0.17
Today's EPS Names:
MAXN, CSTR, ACU, More
Join SI Premium – FREE
Boston Scientific Corporation (NYSE: BSX) reported Q1 GAAP EPS of $0.01, vs. the analyst estimate of $0.04. Non-GAAP EPS came in at 22 cents. Revenue for the quarter came in at $1.93 billion versus the consensus estimate of $1.9 billion.
Sees Q2 EPS of $0.12-$0.15, versus the consensus of $0.08. Sees Q2 revenue of $1.92-$2 billion, versus the consensus of $1.92 billion.
Raises its FY11 EPS guidance from $0.50-$0.60 to $0.58-$0.68, versus the consensus of $0.31. Revenue moves from $7.5-$7.9 billion to $7.6-$7.9 billion, versus the consensus of $7.69 billion.
Sees Q2 EPS of $0.12-$0.15, versus the consensus of $0.08. Sees Q2 revenue of $1.92-$2 billion, versus the consensus of $1.92 billion.
Raises its FY11 EPS guidance from $0.50-$0.60 to $0.58-$0.68, versus the consensus of $0.31. Revenue moves from $7.5-$7.9 billion to $7.6-$7.9 billion, versus the consensus of $7.69 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Procter & Gamble (PG) Tops Q3 EPS by 11c, Revenues Miss
- Elevance Health (ELV) hikes 2024 earnings outlook, shares climb
- American Express (AXP) down despite beating Q1 estimates on top and bottom lines
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
